May Hill Capital LLC Sells 388 Shares of Amgen Inc. $AMGN

May Hill Capital LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 29.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 929 shares of the medical research company’s stock after selling 388 shares during the period. May Hill Capital LLC’s holdings in Amgen were worth $259,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of AMGN. Brighton Jones LLC boosted its position in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in Amgen in the 1st quarter valued at $276,000. Golden State Wealth Management LLC boosted its position in Amgen by 5.5% in the 1st quarter. Golden State Wealth Management LLC now owns 1,933 shares of the medical research company’s stock valued at $602,000 after buying an additional 101 shares during the last quarter. Koshinski Asset Management Inc. boosted its position in Amgen by 1.8% in the 1st quarter. Koshinski Asset Management Inc. now owns 11,302 shares of the medical research company’s stock valued at $3,521,000 after buying an additional 202 shares during the last quarter. Finally, Barnes Dennig Private Wealth Management LLC bought a new position in shares of Amgen in the 1st quarter worth $4,304,000. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.69% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent research reports. Raymond James Financial initiated coverage on Amgen in a research report on Wednesday, September 3rd. They issued a “market perform” rating on the stock. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research report on Monday. Weiss Ratings upgraded Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Bank of America raised their price target on Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research report on Friday, September 26th. Finally, Citigroup raised their price target on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 24th. Six research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $300.94.

Amgen Stock Performance

Shares of Amgen stock opened at $292.09 on Wednesday. The company has a market capitalization of $157.25 billion, a PE ratio of 23.88, a PEG ratio of 2.60 and a beta of 0.49. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $335.88. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The stock’s fifty day simple moving average is $287.82 and its 200 day simple moving average is $287.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping the consensus estimate of $5.28 by $0.74. The business had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s dividend payout ratio (DPR) is presently 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.